PT  - JOURNAL ARTICLE
AU  - Tatapudi, Hanisha
AU  - Das, Rachita
AU  - Das, Tapas K.
TI  - Impact of Vaccine Prioritization Strategies on Mitigating COVID-19: An Agent-Based Simulation Study using an Urban Region in the United States
AID  - 10.1101/2021.03.12.21253447
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.12.21253447
4099  - http://medrxiv.org/content/early/2021/03/12/2021.03.12.21253447.short
4100  - http://medrxiv.org/content/early/2021/03/12/2021.03.12.21253447.full
AB  - Background Approval of novel vaccines for COVID-19 has brought hope and expectations, but not without additional challenges. One central challenge is how to appropriately prioritize the use of limited supply of vaccines. This study evaluates various prioritization strategies and the efficacy of the vaccination campaign underway in the U.S.Methods The study develops a granular agent-based simulation model for mimicking community spread of COVID-19 under various social interventions including full and partial closures, isolation and quarantine, use of face mask and contact tracing, and vaccination. The model is populated with demographic and societal data for an urban community in the U.S. with 2.8 million residents as well as viral parameters. The model tracks daily numbers of infected, hospitalized, and deaths for all census age-groups. Model is calibrated using parameters for viral transmission and level of community circulation of individuals. Published data from the Florida COVID-19 dashboard is used to validate the model. Vaccination strategies are compared using hypothesis test for pairwise comparisons.Results Three prioritization strategies examined are: a close variant of the CDC recommendation, an age-stratified strategy, and a random strategy. The impact of vaccination is also contrasted with a no vaccination scenario. The comparison shows that the ongoing campaign in the U.S. using vaccines developed by Pfizer/BioNTech and Moderna is expected to 1) reduce the cumulative number of infection by 10% and 2) help the pandemic to subside below a small threshold of 100 daily new reported cases sooner by approximately a month. The prioritization strategies when compared with each other showed no significant difference in their impacts on pandemic mitigation.Conclusions Recent explosive growth of the number of new COVID-19 cases in the U.S. continues to shrink the susceptible population. This, we believe, will likely limit the expected number of people that could be prevented from getting infected due to vaccination. A shrinking susceptible pool may also be an attributable reason for the observed lack of statistical difference among the outcomes of the prioritization strategies. However, the invariance of the strategies should give more latitude for decision makers in COVID-19 vaccine distribution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research has not been funded by any grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.ABAgent-basedSEIRSusceptible – exposed – infected – recovered/removedSARS-CoV-2Severe acute respiratory syndrome coronavirus 2COVID-19Coronavirus Disease 2019USFDAUnited States Food and Drug AdministrationCDCCenters for Disease ControlNAESMNationalAcademy of Sciences, Engineering, and MedicineQALYQuality of Life Years